India Pharmaceutical Cold Chain Logistics Market Outlook to 2035

Market Overview

The India Pharmaceutical Cold Chain Logistics Market was valued at USD ~ Billion in 2024 and is anticipated to expand at a CAGR of ~% during 2026-2035. The market is primarily driven by the expanding pipeline of biologics, vaccines, and cell & gene therapies requiring strict temperature control, stringent CDSCO Good Distribution Practice and Schedule M compliance requirements, and continued growth in direct-to-patient e-pharmacy distribution. According to industry estimates, India already ships approximately 60% of the world’s vaccines and 20% of global generic drug volumes, with pharmaceutical exports reaching approximately USD 27.85 billion in FY 2023-24, while the broader India cold chain logistics market was valued at approximately USD 12.6 billion in 2025 and is projected to grow at a CAGR of approximately 8.6% through 2034. Within this, pharmaceuticals and biologics represent the fastest-growing application segment at approximately 6.2% CAGR, and the India cold chain pharmaceutical logistics sub-segment specifically is estimated at approximately USD 0.57 billion in 2024, reflecting continued expansion of validated transport lanes, ultra-low temperature capacity around the Hyderabad and Bengaluru CRDMO clusters, and rising CDSCO audit and documentation requirements.

Market Segmentation

By Service Type

Among these, Transportation continues to represent the largest service category within the India Pharmaceutical Cold Chain Logistics Market, with DHL Supply Chain, Kuehne+Nagel, and Blue Dart Express expanding dedicated temperature-controlled road and air networks to serve pharmaceutical manufacturers and hospital distribution channels. Storage & Warehousing remains a critical foundation of the market, with Snowman Logistics and Stellar Value Chain Solutions continuing to expand GDP-compliant cold storage capacity across major distribution hubs in Mumbai, Bengaluru, and the National Capital Region to support growing biologics and vaccine inventories. Monitoring, Packaging & Value-Added Services represent the fastest-growing service category, driven by rising adoption of IoT-enabled sensors, real-time shipment tracking, and predictive analytics platforms from providers such as TCI Cold Chain Solutions and ColdEX Logistics, as pharmaceutical companies increasingly prioritize shipment visibility and chain-of-custody verification for high-value biologics and cell & gene therapy payloads.

By Temperature Range

The Refrigerated (2°C-8°C) segment remains the largest temperature range category within the India Pharmaceutical Cold Chain Logistics Market, encompassing the majority of vaccines, insulin, and biologics distributed nationally under the National Immunization Program, with providers such as Coldman Logistics and Gubba Cold Storage supplying validated passive and active packaging systems to maintain precise temperature control. The Ultra-Cold & Cryogenic segment is witnessing the fastest growth, driven by the expansion of vaccine distribution and the gradual commercialization of cell & gene therapies that require storage as low as -196°C, particularly around the Hyderabad and Bengaluru CRDMO clusters, with multinational and domestic providers expanding cryogenic shipper fleets and liquid nitrogen dry-vapor logistics networks to serve this emerging segment. The Frozen segment continues to grow steadily, supported by rising distribution of frozen biologics and specialty compounded medications across hospital and specialty pharmacy networks.

Competitive Landscape

The India Pharmaceutical Cold Chain Logistics Market is moderately fragmented, with DHL Supply Chain, Snowman Logistics, TCI Cold Chain Solutions, Blue Dart Express, and Kuehne+Nagel together controlling a meaningful share of specialty pharmaceutical distribution volume, though the top five players together control barely a fifth of overall national cold storage capacity, reflecting a landscape that continues to favor regional specialists. Competition is primarily based on CDSCO GDP and regulatory compliance certifications, temperature-range service breadth, network coverage, real-time monitoring capability, and long-term relationships with pharmaceutical manufacturers and hospital networks. DHL Supply Chain maintains a strong position through its planned EUR 500 million investment in 12 million square feet of new automated warehousing capacity, while Snowman Logistics continues to expand its 45-warehouse, fully IoT-visible reefer network with 100% generator back-up to support GDP compliance during India’s frequent power interruptions. TCI Cold Chain Solutions continues to expand its Pharma Cold Chain Express service featuring GPS-enabled reefers and data loggers following a USD 42 million investment in a dedicated Gurugram pharma hub, while Coldman Logistics, ColdEX Logistics, and Gubba Cold Storage compete on multi-temperature warehousing density and last-mile delivery reach across more than 200 cities. Global freight forwarders including Kuehne+Nagel, CEVA Logistics, and Rhenus Logistics continue to expand dedicated pharmaceutical verticals to capture growing demand for GDP-compliant end-to-end distribution across the country, as CDSCO’s tightening validated-lane and continuous data-logging mandates raise the compliance bar for smaller unorganized operators.

India Pharmaceutical Cold Chain Logistics Market Analysis

Growth Drivers

Expansion of Biologics, Vaccines, and Cell & Gene Therapy Pipelines

The India Pharmaceutical Cold Chain Logistics Market continues to be shaped decisively by the pharmaceutical industry’s accelerating shift toward biologics, monoclonal antibodies, and cell & gene therapies, which are highly sensitive to temperature fluctuations and require strict temperature control throughout storage and transportation. India’s position as the world’s largest vaccine producer, shipping approximately 60% of global vaccine volumes, has long underscored the necessity for robust cold chain infrastructure, prompting companies to expand cold storage capabilities and invest in innovative packaging solutions. According to industry estimates, the maturing biologics pipeline is lifting demand for ultra-low temperature space below -20°C, particularly around the Hyderabad and Bengaluru CRDMO clusters, while pharmaceutical exports reaching approximately USD 27.85 billion in FY 2023-24 are driving rising demand for temperature-controlled distribution of vaccines, insulin, monoclonal antibodies, and specialty cancer therapies. The gradual expansion of the cell & gene therapy market, supported by government-backed biomanufacturing incentives under Production Linked Incentive (PLI) schemes, has directly encouraged specialty logistics providers to expand cryogenic shipping capacity and liquid nitrogen dry-vapor fleets.

Stringent Regulatory Compliance and Growth in E-Pharmacy Distribution

Stringent regulations for maintaining accurate temperature control for temperature-sensitive drugs, including CDSCO Good Distribution Practice guidelines and Schedule M and Schedule H requirements under the Drugs and Cosmetics Act, continue to be a critical driver of investment in validated cold chain infrastructure across India. CDSCO’s tightening mandates for validated transport lanes, continuous data logging, and audit trails are raising the compliance bar and pushing manufacturers toward specialty logistics partners with proven GDP compliance track records, exemplified by Snowman Logistics retrofitting its full warehouse network with 100% generator back-up and TCI Cold Chain Solutions integrating GPS-enabled reefers and data loggers across its Pharma Cold Chain Express service. The continued expansion of e-pharmacy platforms, with the online pharmacy market projected to reach approximately USD 3 billion by 2025, is also driving demand for last-mile temperature-controlled delivery capability, as patients increasingly receive biologics, insulin, and specialty medications directly at home rather than through traditional retail pharmacy channels.

Market Challenges

High Capital Expenditure and Cold Storage Infrastructure Constraints

The India Pharmaceutical Cold Chain Logistics Market faces significant challenges from the high capital expenditure required to build and maintain GDP-compliant cold storage facilities, temperature-controlled fleets, and validated packaging systems across a geographically vast and diverse national network, where the five largest organized players together control barely 20 lakh metric tons out of nearly 395 lakh metric tons of total national cold storage capacity. Cold storage specialists such as Snowman Logistics and Stellar Value Chain Solutions must continue to invest heavily in energy-intensive refrigeration infrastructure to support growing biologics and vaccine inventories, while power reliability and energy cost volatility remain a persistent downside risk, requiring redundant generator back-up systems to maintain unbroken cold chain integrity. Temperature excursion risk remains a persistent operational challenge, as even brief deviations from validated temperature ranges during transit or storage in India’s tropical and sub-tropical climate zones can compromise product efficacy and trigger costly product recalls, requiring continuous investment in redundant monitoring and contingency systems across the value chain.

Last-Mile Delivery Complexity and Driver Shortages

Last-mile delivery complexity in rural and Tier 2/3 markets continues to increase deployment challenges across the India Pharmaceutical Cold Chain Logistics Market, as providers must maintain unbroken temperature control across the final delivery leg to hospitals, clinics, pharmacies, and increasingly, patients’ homes, despite significant distances and inconsistent road and power infrastructure outside major metropolitan corridors. Persistent shortages of qualified commercial drivers and skilled cold chain logistics personnel continue to constrain network capacity and increase labor costs across the industry. Packaging waste and sustainability pressures present an additional operational challenge, as single-use passive packaging systems generate significant waste volumes, prompting regulatory and customer pressure for providers to transition toward reusable and recyclable packaging solutions. These operational bottlenecks continue to extend delivery timelines and increase costs across the industry, requiring providers to maintain larger safety buffers and redundant capacity to offset network disruptions.

Market Opportunities

Growth in Cell & Gene Therapy Logistics and Emerging Packaging Technologies

The gradually expanding cell & gene therapy market in India presents substantial opportunities for companies developing specialized cryogenic and dry-vapor shipping capabilities beyond conventional refrigerated and frozen logistics. Specialty providers with global cryogenic networks are well positioned to capture growing demand for chain-of-custody verification and cryogenic transport as these advanced therapies move from clinical trials toward broader commercial distribution across India’s leading CRDMO and biomanufacturing clusters in Hyderabad and Bengaluru. Expansion of reusable and sustainable packaging solutions, including vacuum-insulated and phase-change material systems, presents a growing opportunity as pharmaceutical manufacturers and logistics providers face increasing pressure to reduce single-use packaging waste while maintaining validated temperature performance across India’s extended transit times and distances.

AI-Enabled Monitoring, Biosimilars Growth, and Export Infrastructure Expansion

The continued expansion of AI and IoT-enabled predictive monitoring platforms presents significant opportunities for companies with strong technology and data analytics capabilities, as pharmaceutical manufacturers increasingly demand real-time shipment visibility and predictive risk analytics rather than passive temperature logging alone. Growth in India’s biosimilars market, which requires cold chain distribution comparable to reference biologics, is expanding the addressable market for specialty logistics providers as India continues to account for approximately 20% of global generic drug exports. Companies capable of combining strong domestic network coverage, CDSCO regulatory compliance expertise, and advanced monitoring technology are well positioned to capture growing demand as pharmaceutical manufacturers increasingly favor PLI-linked domestic biomanufacturing capacity that shortens cold chain distribution distances and strengthens India’s position as a global pharmaceutical export hub.

Future Outlook

The India Pharmaceutical Cold Chain Logistics Market is expected to witness robust expansion over the forecast period, supported by continued growth in biologics, vaccines, and cell & gene therapy pipelines, stringent CDSCO regulatory compliance requirements, and rising direct-to-patient e-pharmacy distribution. Continued investment in cryogenic and ultra-cold shipping capacity, AI-enabled predictive monitoring platforms, and reusable packaging technologies is expected to further strengthen the market’s competitive landscape. Growing regulatory emphasis on chain-of-custody verification and sustainability, combined with continued organized-sector consolidation and capacity expansion around the Hyderabad and Bengaluru CRDMO clusters, will continue to reshape infrastructure investment decisions and competitive dynamics across the industry through 2035.

Major Players 

• DHL Supply Chain India (Life Sciences & Healthcare) 
• Kuehne+Nagel India 
• FedEx Logistics India 
• Blue Dart Express Ltd. 
• Snowman Logistics Ltd. 
• TCI Cold Chain Solutions (Transport Corporation of India Ltd.) 
• Gati-Kausar (Allcargo Gati) 
• ColdEX Logistics Pvt. Ltd. 
• Coldman Logistics Pvt. Ltd. 
• Stellar Value Chain Solutions Pvt. Ltd. 
• Gubba Cold Storage Pvt. Ltd. 
• Mahindra Logistics Ltd. 
• CJ Darcl Logistics Ltd. 
• Rhenus Logistics India Pvt. Ltd. 
• CEVA Logistics India

Key Target Audience 

• Pharmaceutical & Biotech Manufacturers 
• Specialty Logistics and Cold Chain Service Providers 
• Hospitals, Clinics, and Specialty Pharmacy Networks 
• Clinical Research Organizations and Academic Institutes 
• Investment and Venture Capitalist Firms 
• Government and Regulatory Bodies (Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, National Health Mission) 
• Cold Chain Packaging and Monitoring Technology Suppliers 
• Airlines, Freight Forwarders, and Warehousing Operators

Research Methodology

Step 1: Identification of Key Variables

The research process begins with identifying the complete ecosystem of the India Pharmaceutical Cold Chain Logistics Market, including specialty logistics providers, cold storage operators, packaging and monitoring technology suppliers, pharmaceutical manufacturers, and regulatory authorities. Extensive secondary research is conducted using company annual reports, government publications, regulatory agency disclosures, industry journals, and proprietary databases to determine the variables influencing market demand, pricing, shipment volume, and technological developments.

Step 2: Market Analysis and Construction

Historical market information is collected and analyzed to estimate market size, shipment volume, application-wise demand, and pricing trends. A combination of top-down and bottom-up approaches is used to estimate market revenues and validate segment-level performance. Consumption patterns across manufacturers, hospitals, pharmacies, and research institutes are evaluated to establish an accurate representation of the industry.

Step 3: Hypothesis Validation and Expert Consultation

The preliminary findings are validated through Computer-Assisted Telephone Interviews (CATIs) and structured discussions with logistics providers, cold storage operators, pharmaceutical procurement managers, regulatory experts, and senior executives operating within India’s pharmaceutical cold chain logistics industry. These interviews help verify market assumptions, competitive developments, technology adoption trends, pricing dynamics, and future investment opportunities while refining the overall market estimates.

Step 4: Research Synthesis and Final Output

The final stage integrates insights obtained from primary interviews with quantitative information collected through secondary sources. Data triangulation techniques are applied to reconcile differences between supply-side and demand-side estimates, ensuring robust market forecasting. The report is then reviewed through multiple quality assurance checkpoints to deliver a comprehensive analysis covering market size, segmentation, competitive landscape, future outlook, and strategic recommendations for industry stakeholders.